Eli Lilly and Company $LLY Shares Acquired by Sapient Capital LLC

Key Points

• Sapient Capital LLC increased its stake in Eli Lilly and Company by 0.8%, acquiring an additional 9,903 shares, bringing its total holdings to approximately 1.2 million shares, valued at about $949.8 million.
• Insider transactions included EVP Daniel Skovronsky and Director Gabrielle Sulzberger purchasing shares at $634.40 and $641.18 per share, respectively, indicating confidence in the company's stock.
• Eli Lilly's recent earnings report exceeded expectations with $6.31 EPS, beating estimates by $0.72, while quarterly revenue surged by 37.6% year-over-year to $15.56 billion.

Sapient Capital LLC grew its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 0.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,218,487 shares of the company's stock after buying an additional 9,903 shares during the period. Eli Lilly and Company accounts for approximately 17.0% of Sapient Capital LLC's holdings, making the stock its biggest position. Sapient Capital LLC owned 0.13% of Eli Lilly and Company worth $949,847,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Seaside Wealth Management Inc. raised its position in shares of Eli Lilly and Company by 3.9% in the 2nd quarter. Seaside Wealth Management Inc. now owns 691 shares of the company's stock worth $539,000 after purchasing an additional 26 shares during the last quarter. GSG Advisors LLC raised its position in shares of Eli Lilly and Company by 8.0% in the 2nd quarter. GSG Advisors LLC now owns 448 shares of the company's stock worth $349,000 after purchasing an additional 33 shares during the last quarter. Mirador Capital Partners LP raised its position in shares of Eli Lilly and Company by 2.6% in the 2nd quarter. Mirador Capital Partners LP now owns 1,413 shares of the company's stock worth $1,101,000 after purchasing an additional 36 shares during the last quarter. Baron Wealth Management LLC raised its position in shares of Eli Lilly and Company by 2.4% in the 2nd quarter. Baron Wealth Management LLC now owns 642 shares of the company's stock worth $501,000 after purchasing an additional 15 shares during the last quarter. Finally, Goelzer Investment Management Inc. raised its position in shares of Eli Lilly and Company by 1.3% in the 2nd quarter. Goelzer Investment Management Inc. now owns 557,659 shares of the company's stock worth $434,712,000 after purchasing an additional 7,349 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CEO David A. Ricks acquired 1,632 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the acquisition, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. The trade was a 0.30% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Daniel Skovronsky acquired 1,000 shares of the company's stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. The trade was a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders have bought 4,514 shares of company stock worth $2,894,841 over the last quarter. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded down $9.41 during trading on Friday, reaching $753.52. The stock had a trading volume of 7,319,147 shares, compared to its average volume of 3,181,974. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The business has a fifty day moving average price of $738.37 and a 200-day moving average price of $770.79. The stock has a market cap of $713.17 billion, a PE ratio of 49.25, a PEG ratio of 1.05 and a beta of 0.47. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $939.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the previous year, the company posted $3.92 earnings per share. The firm's revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were paid a dividend of $1.50 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.8%. Eli Lilly and Company's dividend payout ratio is presently 39.22%.

Analyst Ratings Changes

A number of analysts have recently issued reports on LLY shares. Cantor Fitzgerald dropped their price target on shares of Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating on the stock in a report on Wednesday, August 13th. Hsbc Global Res raised shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a report on Wednesday, August 27th. Erste Group Bank downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Berenberg Bank reaffirmed a "hold" rating and set a $830.00 price target (down previously from $970.00) on shares of Eli Lilly and Company in a report on Wednesday. Finally, DZ Bank raised shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 14th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $939.61.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.